Despite the high prevalence of gastroesophageal reflux disease (GERD) and, to a lesser degree, Barrett’s esophagus in the Western world, there are still many unknowns with regard to the epidemiology, natural history, and appropriate treatments for these conditions. There is a significant amount of ongoing research into endoscopic treatment modalities in an attempt to reduce the need for medical therapy for GERD. Meanwhile, the underlying biology of Barrett’s carcinogenesis is incompletely understood, as is the ideal treatment for Barrett’s esophagus and advanced neoplasia.
References
1
Pace F, Bollani S, Molteni P. et al .
Natural history of gastro-oesophageal reflux disease without oesophagitis (NERD) – a reappraisal 10 years on.
Dig Liver Dis.
2004;
36
111-115
2
Locke 3rd G R.
Natural history of nonerosive reflux disease. Is all gastroesophageal reflux disease the same? What is the evidence?.
Gastroenterol Clin North Am.
2002;
31
S59-S66
5
Ruhl C E, Everhart J E.
Overweight, but not high dietary fat intake, increases risk of gastroesophageal reflux disease hospitalization: the NHANES I Epidemiologic Followup Study. First National Health and Nutrition Examination Survey.
Ann Epidemiol.
1999;
9
424-435
6
El-Serag H B, Petersen N J, Carter J. et al .
Gastroesophageal reflux among different racial groups in the United States.
Gastroenterology.
2004;
126
1692-1699
9
McNamara D A, O’Donohoe M K, Horgan P G. et al .
Symptoms of oesophageal reflux are more common following laparoscopic cholecystectomy than in a control population.
Ir J Med Sci.
1998;
167
11-13
11
Manifold D K, Anggiansah A, Owen W J.
Effect of cholecystectomy on gastroesophageal and duodenogastric reflux.
Am J Gastroenterol.
2000;
95
2746-2750
13
Aanen M C, Weusten B L, Numans M E. et al .
Diagnostic value of the proton pump inhibitor test for gastro-oesophageal reflux disease in primary care.
Aliment Pharmacol Ther.
2006;
24
1377-1384
14
des Varannes S B, Sacher-Huvelin S, Vavasseur F. et al .
Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting.
World J Gastroenterol.
2006;
12
2569-2573
15
Numans M E, Lau J, de Wit N J. et al .
Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics.
Ann Intern Med.
2004;
140
518-527
16
Bytzer P, Jones R, Vakil N. et al .
Evaluation of the proton pump inhibitor (PPI) test for the diagnosis of GERD: Results from the Diamond study.
Gastroenterology.
2008;
134
A100
17
Morana E, Guida L, Cavallaro L G. et al .
Gastrin-17 (G-17): a serological bio-marker for diagnosis of gastro-esophageal reflux disease (GERD).
Gastroenterology.
2008;
134
A101
18
Monkemuller K, Neumann H, Nocon M. et al .
Serum gastrin and pepsinogens do not correlate with the different grades of severity of GERD: a matched case-control study.
Aliment Pharmacol Ther.
2008;
in press
20
Pohl D, Mueller M K, Wildi S. et al .
Gastroesophageal reflux and esophageal peristalsis before and after gastric bypass surgery – an interim analysis of combined impedance-pH and high resolution manometry data.
Gastroenterology.
2008;
134
A13
21
Kubo A, Corley D A.
Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis.
Cancer Epidemiol Biomarkers Prev.
2006;
15
872-878
24
Hatlebakk J G, Lundell L R, Galmiche J P. et al .
Initial control of acid reflux after laparoscopic anti-reflux surgery (LARS) compared to chronic use of esomeprazole (ESO) 20 – 40 mg daily.
Gastroenterology.
2008;
134
A125
25
Pleskow D, Rothstein R, Kozarek R. et al .
Endoscopic full-thickness plication for the treatment of GERD: five-year long-term multicenter results.
Surg Endosc.
2008;
22
326-332
26
Pleskow D, Rothstein R, Kozarek R. et al .
Endoscopic full-thickness plication for the treatment of GERD: long-term multicenter results.
Surg Endosc.
2007;
21
439-444
27
Corsetti M, Passaretti S M, Di Pietro S. et al .
Effect of the EsophyX device for endoluminal fundoplication on symptoms, esophageal manometry and pH-impedence of patients with gastro-esophageal reflux.
Gastroenterology.
2008;
134
A13
29
de Jonge P J, van Blankenstein M, Looman C W. et al .
Trends in the incidence of Barrett’s esophagus in the Netherlands 1991 – 2006.
Gastroenterology.
2008;
134
A39
30
Conio M, Blanchi S, Lapertosa G. et al .
Long-term endoscopic surveillance of patients with Barrett’s esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study.
Am J Gastroenterol.
2003;
98
1931-1939
31
Drewitz D J, Sampliner R E, Garewal H S.
The incidence of adenocarcinoma in Barrett’s esophagus: a prospective study of 170 patients followed 4.8 years.
Am J Gastroenterol.
1997;
92
212-215
32
Sikkema M, Kerkhof M, Steyerberg E W. et al .
Prospective multicenter study on the incidence of neoplastic progression in Barrett esophagus patients.
Gastrointest Endosc.
2008;
67
AB75
33
Wang K K, Sampliner R E.
Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus.
Am J Gastroenterol.
2008;
103
788-797
34
McCallum A L, Macpherson M, Jenkins J T. et al .
Autofluorescence assessment in the surveillance of Barrett’s oesophagus: a randomised trial comparing standard 4 quadrant biopsy and AF directed biopsy.
Gastroenterology.
2008;
134
A63
35
Wolfsen H C, Crook J E, Krishna M. et al .
Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett’s esophagus.
Gastroenterology.
2008;
135
24-31
36
Dunbar K B, Montgomery E A, Okolo P. et al .
Confocal laser endomicroscopy in Barrett’s esophagus and associated neoplasia: a prospective randomized controlled crossover trial.
Gastrointest Endosc.
2008;
67
AB97
38
Sikkema M, Kerkhof M, Steyerberg E W. et al .
Flow cytometry in Barrett esophagus (Cybar Study): a prospective cohort study.
Gastroenterology.
2008;
134
A110
40
Berman D M, Karhadkar S S, Maitra A. et al .
Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours.
Nature.
2003;
425
846-851
41
Oh D S, DeMeester S R, Mori R. et al .
Sonic Hedgehog gene expression in Barrett’s esophagus and esophageal adencoarcinoma.
Gastroenterology.
2008;
134
A150
42
Shaheen N J, Sharma P, Overholt B F. et al .
A randomized, multicenter, sham-controlled trial of radiofrequency ablation (RFA) for subjects with Barrett’s esophagus (BE) containing dysplasia: interim results of the AIM Dysplasia Trial.
Gastroenterology.
2008;
134
A37
43
Reed M F, Tolis Jr G, Edil B H. et al .
Surgical treatment of esophageal high-grade dysplasia.
Ann Thorac Surg.
2005;
79
1110-1115; discussion 1110 – 1115
44
Konda V J, Chennat J S, Ross A S. et al .
Low rate of invasive cancer in patients undergoing mucosectomy for Barrett’s esophagus (BE) and high grade dysplasia (HGD) or intramucosal carcinoma (IMC).
Gastrointest Endosc.
2008;
67
AB76
46
Manner H, May A, Pech O. et al .
Are patients with ”low risk“ submucosal invasion of early Barrett’s carcinoma eligible for curative endoscopic therapy? Outcomes of endoscopic therapy and surgery in 80 patients with suspected or definite diagnosis of submucosal Barrett’s cancer.
Gastrointest Endosc.
2008;
67
AB75
